289results about "Plant growth regulators" patented technology

The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood. Examples of conditions which may benefit from increased blood flow include, but are not limited to, erectile dysfunction, hair loss, female sexual dissatisfaction, sagging facial or other body tissue, peripheral vascular disease including claudication, neuropathy, skin ulcers, bone healing, wound healing, viral and bacterial infection, and skin grafting.

A disposable child sized cleaning implement is provided. The disposable child sized cleaning implement is releasably carrying a personal care composition which comprises an biological extract.

Dietary supplements and methods for management and control of body weight comprising at least one liver protecting agent and at least one mushroom in the form of powder, extract, or combinations thereof.

A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably biocompatible. The polymerizing molecule can, for example. be dihydroxyphenyl-L-alanine (DOPA) or tyrosine. The composition can also include a second component synthesized by reacting at least one core molecule having a plurality of reactive hydrogen groups with at least one multi-isocyanate functional molecule to create a conjugate including terminal isocyanate groups. The conjugate molecule is reacted with a second polymerizing molecule that is adapted to undergo a free radical polymerization. The second polymerizing molecule includes a reactive hydrogen to react with the isocyanate groups of the conjugate. The second polymerizing molecule retains the ability to undergo the free radical polymerization after reaction with the conjugate. In several embodiments, the first polymerizing molecule and the second polymerizing molecule are the same and dihydroxyphenyl-L-alanine (DOPA) or tyrosine.

The present invention provides prodrug compounds of diaryldiazepine drug compounds.

Macrolide compounds, such as the FK506 Substance and its related compounds, are provided for the prevention or treatment of eye diseases, particularly glaucoma. Composition containing such compounds is also disclosed.

The present invention calls utilized genes differentially expressed in target cells to design vaccines to generate an immune response. Unlike prior art methods that seek to identify antigenic proteins from phenotypic analysis, the subject method applies functional genomics for antigen identification. The method is exemplified herein and therefore provides compositions and methods for inducing an immune response against gp 100 melanoma cells and for inducing an immune response against HER-2+cells. Cancer vaccines and adoptive immunotherapeutic methods to treat and prevent conditions associated with the presence of these cells in a subject also are provided. The methods can be practiced by administering the appropriate gene or cancer vaccine, antibody, protein, polypeptide, antigen-presenting cell or immune effector cell.

The invention discloses a plant antifreezer and its preparation method. The plant antifreezer is preparegggggd from the following components of: by weight, 0.5-0.97% of glucose, 0.5-0.97% of cane sugar, 0.2-0.5% of potassium dihydrogen phosphate, 0.18-0.21% of novel monomolecular lipid film, 0.06-0.17% of paclobutrazol, 0.2-0.33% of amino acid, 0.02-0.05% of 6-benzylamino-purine, 0.01-0.05% of rapin, 46-48.4% of glycerin and 48.6-51% of water. The plant antifreezer provided by the invention is nontoxic and harmless, doesn't pollute the environment, and can be directly sprinkled on plant leaf surfaces, flowers and flower bus. The preparation method is simple and requires low cost. Effective antifreezing period can reach 15-20 days. By the adoption of the plant antifreezer, lower temperature freeze injury resistance of plants can be enhanced and the freeze injury can be rapidly mitigated after freeze injury. The plant antifreezer provided by the invention can be used to form a protection film on the surface of a plant and protect the plant from cold, and has an effect of preventing diseases.

The invention relates to a cyclic production method of glyphosate, belonging to the technical field of pesticide production techniques. The production method comprises steps as follows: the raw material dimethyl phosphite is subjected to an alkyl ester method to obtain glyphosate and a glyphosate mother solution; the glyphosate mother solution is treated to obtain a secondary alkali mother solution; the secondary alkali mother solution is subjected to catalytic preoxidation, high-temperature high-pressure air electrocatalytic degradation and liquid membrane extraction to obtain a liquid membrane concentrated solution and a saliferous liquid membrane diluted solution; the liquid membrane concentrated solution is subjected to active carbon decoloration, concentration by evaporation, and high temperature polymerization to obtain sodium tripolyphosphate; the saliferous liquid membrane diluted solution is filtered by a nanofiltration membrane to obtain a membrane concentrated solution and a membrane diluted solution; the membrane concentrated solution returns to the catalytic preoxidation step to be recovered; the membrane diluted solution enters an MVR (mechanical vapor recompression) system to be subjected to concentration by evaporation, thereby obtaining sodium chloride crystal, distilled water and a mother solution; and the sodium chloride crystal, distilled water and mother solution are respectively utilized. The invention lowers the production cost, enhances the utilization ratio of the product, reduces the discharge of waste liquor in the glyphosate production procedure, is environment-friendly, and has obvious comprehensive economic benefit and social benefit.

A fermentation process for the production of ethanol from natural sources, such as corn, comprising introducing a fermentable sugar and an inoculant, and a bacteriophage cocktail into a fermentation system and introducing a cocktail comprising one or more lytic bacteriophage is added to one or more of the fermentable sugar, the inoculant, or the fermentation system. Bacteriophages that infect and lyse the bacteria that contaminate fermentable sugars are selected. The bacteriophage cocktail is added in an amount effective to substantially prevent growth of these bacteria.

In on aspect, the invention includes a microcarrier bead having a porous three-dimensional core having (a) a polymeric porous three-dimensional body having porosity of about 15 to about 90% such that at least 99% of pores are interconnected and have diameters of at most 200 microns, (b) an outer protective layer and optionally (c) a filler. In another aspect, the invention includes a method of making an artificial scaffold wherein a scaffolding material is extruded into a coolant and thereby creating a porous material having a porosity of between 15-90% such that at least 99% of pores are interconnected and have diameters of at most 200 microns.

This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.

This invention relates to bioadhesive compositions, which are particularly, but not exclusively, useful for making medical electrodes and to medical electrodes based on such compositions. A first bioadhesive composition comprises: 10 (i) 28-60 wt % of a copolymer comprising repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids and repeating units derived from one or more olefinically unsaturated carboxylic acids, the ratio by weight of the sulphonic acid units to the carboxylic acid units being from 30:1 to 1:1; 15 (b).

The present invention is directed to a hard capsule filled with a solution containing an active ingredient, characterized in that the solution contains an inorganic chloride and has a water content (w) of 10<w≦80% and a water activity (a) of 0.50≦a≦0.90, and that the capsule is made of a base material containing a cellulose derivative. According to the present invention, a solution having high water content can be encapsulated, with its solution form being maintained. Thus, the present invention enables provision of a product which does not impair properties and stability of a drug or a similar substance, and does not impair sensation upon intake or eating sensation.

The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.

We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.

The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets.

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

The present invention relates to a biological control strain AR156 for preventing and treating root-knot nematodes of greenhouse vegetable, belonging to plant protection technical field. The bacteria is bacillus sp., which is cultivated in PDA culturing liquor under 37 degree and 180rpm, then is centrifuged 10min under 6000rpm. Picking wet bacteria and bacteria storage liquid is prepared into bacteria agent according to 1:40 (g/ml)proportion. The living bacteria concentration is 1*109-1*1012cfu/ml.The effective rate of the bacteria agent amount to 58-75% for preventing root-knot nematodes of cucumber, towel gourd, tomato etc, and yield increase more than 30-50%. The bacteria agent can also treat wilt, epidemic disease and soil hardening. The bacteria agent can be sprayed, composted and irrigated to root.

The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in said human placental cell bank according to the present invention, a method for preparing human cord blood serum, use of human placental cells obtained by said method for processing human placental cell sample or human placental cell bank established by said method for banking human placental cells in treating human dysfunction and diseases due to cell injury or cell malfunction, as well as a method for treating human dysfunction and diseases due to cell injury or cell malfunction.

The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.